PAVmed, Inc. PAVM 深 沪
等待开盘 01-22 09:30:00 美东时间
12.05
+5.860
+94.67%
华盛通- 最 高28.44
- 今 开17.99
- 成交量 5530.51万股
- 最 低 11.58
- 昨 收 6.19
- 总市值 1191.87万
- 52周最高 28.44
- 市盈率 静 0.81
- 换手率 5591.45%
- 52周最低 6.00
- 委 比 92.88%
- 总股本 98.91万
- 历史最高 6841.5963
- 量 比 1359.62
- 振 幅 272.37%
- 历史最低 6.00
- 每 手 1
- 风险率 4.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers PAVmed (NASDAQ:PAVM) stock increased by 250.7% to $21.71 during Wednes...
今天 01:05
Why Is PAVmed Stock Skyrocketing Wednesday?
Pavmed Inc. (PAVM) surges as its subsidiary Lucid Diagnostics (LUCD) secures a contract with VA for its cancer prevention test.
今天 00:22
Lucid Diagnostics Wins VA Contract For EsoGuard, Expanding Esophageal Cancer Screening Across Nationwide VA Healthcare System
Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it has been
01-21 21:10
PAVmed announces 1-for-30 reverse stock split
PAVmed (PAVM) will conduct a 1-for-30 reverse stock split of its common stock, effective on January 2, 2026, at 12:01 a.m. Eastern Time. The reverse stock split is intended to bring the company into c...
2025-12-30 22:29
PAVmed To Execute 1-For-30 Reverse Stock Split, Effective January 2, 2026
PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced it
2025-12-30 22:03
PAVmed Announces Reverse Stock Split
NEW YORK, Dec. 30, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, di...
2025-12-30 22:01
美股大行评级 | 超配！大摩上调回声星通信评级；汽车地带、CBRL、金宝汤、家得宝等遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8美元升至8.25美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12.5美元升至13美元
2025-12-11 10:33
Ascendiant Capital Maintains Buy on PAVmed, Lowers Price Target to $17
Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and lowers the price target from $20 to $17.
2025-12-10 18:27
PAVmed Approves Reverse Stock Split Amendment
PAVmed ( ($PAVM) ) has issued an update. On December 5, 2025, PAVmed Inc. held ...
2025-12-06 05:53
PAVmed Q3 Adj. EPS $(0.02) Beats $(0.20) Estimate, Sales $5.000K Miss $12.500K Estimate
PAVmed (NASDAQ:PAVM) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.20) by 90 percent. This is a 96.3 percent increase over losses of $(0.54) per share from the same
2025-11-13 21:48
